SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

mF International ($MFI) is trending after announcing a $500 million PIPE to support a Bitcoin-backed digital asset strategy, fueling discussions about its potential and comparisons to other crypto-related plays. While some express concerns about dilution and potential manipulation, others highlight the company's low market cap and see it as a buying opportunity, drawing parallels to previous high-flying stocks.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards amid concerns about its Bitcoin holdings and potential exclusion from major indices, sparking debate about a possible collapse. The community is discussing the correlation between Strategy's stock price and Bitcoin's performance, as well as CEO Michael Saylor's strategy and the company's future amidst market volatility.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as its community rallies around its "infectious" meme culture on the SOL network. Active community members are creating buzz and expressing excitement about its potential, particularly its strong community and unique meme-driven approach, with many believing $PMV is on track to reach a $1M market cap.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

Tenax Therapeutics is trending due to recent insider buying and anticipation surrounding upcoming Phase 3 data. Community members are discussing the low float, high institutional ownership, and potential for a significant short squeeze, with some mentioning Steve Cohen's involvement and a target price of $100 or more. There is optimism related to the company's cash position and potential FDA approval of their medicine.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the crypto market experiences volatility, leading to discussions about potential support levels and future price movements. Community members are actively debating whether this is a buying opportunity or a sign of further declines, while also speculating on the impact of macroeconomic factors and institutional involvement. Some traders point to technical indicators and chart patterns, adding to the uncertainty and varied opinions surrounding Bitcoin's short-term trajectory.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

SCLX is trending due to community discussion around the Dream Bowl meme coin distribution to shareholders and Nasdaq's refusal to announce the ex-dividend date, leading to speculation about the nature of the dividend. Some investors believe shorts will be squeezed, while others are concerned about the legitimacy of the dividend and potential regulatory issues. The community is also discussing SCLX's relationship with Datavault AI and the potential implications of their partnership.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions is trending as investors discuss large dark pool transactions and options activity, suggesting potential institutional interest. Some community members believe the stock is oversold, while others point to value tech and divergence as reasons to consider $MSI. The company's profitability and potential for a rebound are also being debated.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community members discuss potential short squeezes and the stock's valuation relative to its cash holdings. Some traders express frustration with the stock's performance amid broader market gains, while others remain optimistic about a potential turnaround and are closely monitoring upcoming earnings. Ryan Cohen's actions and influence continue to be a significant point of discussion among investors.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB is trending as a newly listed token on major exchanges, with the community drawing comparisons to early Bitcoin and anticipating potential gains, especially as it relates to the ICP blockchain; some suggest $BOB could outperform $ICP. Discussions revolve around its limited supply, upcoming halving, and potential for increased attention and value.

WillScot Holdings Corp. provides modular and portable storage services. The firm offers furniture rental, transportation and logistics, storage & facilities services and commercial real estate services. It offers turnkey office space and storage solutions for temporary applications in the commercial and industrial, construction, retail, education, health care, government, transportation, security and energy sectors. The company was founded by on June 26, 2015 and is headquartered in Scottsdale, AZ.

WillScot Holdings Corp. - Ordinary Shares - Class A

WillScot Mobile Mini Holdings Corp

WillScot Mobile Mini is trending due to a recent analyst upgrade from Baird, citing a 'watershed' quarter, which has boosted investor confidence. The community is also discussing the company's balance sheet and potential for dividend payouts. Additionally, the stock's oversold RSI is sparking conversations about a possible reversal.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Caribou Biosciences (NASDAQ:CRBU) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus...

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -147.37% and -71.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Brookline Capital Management Predicts CRBU FY2026 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Analysts at Brookline Capital Management dropped their FY2026 earnings per share (EPS) estimates for Caribou Biosciences in a research note...

<p>Shares of Caribou Biosciences, Inc. (CRBU) jumped 52% in the pre-market session on Monday after the company announced positive data from early-stage trials of two of its CAR-T cell therapies.</p><p>While one of the therapies was evaluated for the treatment of multiple myeloma, a blood cancer of plasma cells, the other was assessed in B-cell non-Hodgkin lymphoma (NHL), a cancer that originates in B lymphocytes, a type of white blood cell that fights infection.</p><h2 class="st-heading-2">Study In Multiple Myeloma</h2><p>The company said that the first clinical data for its CB-011 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179047/0/en/Caribou-Biosciences-Announces-Positive-Data-from-CaMMouflage-Phase-1-Trial-of-CB-011-in-Multiple-Myeloma.html">highlights</a> its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.</p><p>The company now expects to advance the program into the dose expansion phase by the end of the year. In the dose escalation portion of the trial, CB-011 had a manageable safety profile across all dose levels, the company noted. The portion of the trial evaluated the safety and efficacy of CB-011 in 48 patients at multiple dose levels and following two different chemotherapy treatments.</p><h2 class="st-heading-2">Study In B-cell non-Hodgkin lymphoma</h2><p>Meanwhile, data from an early-stage trial of vispacabtagene regedleucel (Vispa-cel) demonstrated the efficacy and durability of the cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179104/0/en/Caribou-Biosciences-Announces-Positive-Data-from-ANTLER-Phase-1-Trial-Demonstrating-Efficacy-and-Durability-of-Vispa-cel-CB-010-an-Allogeneic-CAR-T-Cell-Therapy-on-Par-with-Autolog.html">said</a>. Vispa-cel was generally well-tolerated, allowing for administration in the outpatient setting, the company added.</p><p>“We believe that with these results, Caribou has achieved what the field has long sought — strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use,” said CEO Rachel Haurwitz.</p><p>Allogeneic CAR-T cell therapy is a type of "off-the-shelf" cancer treatment that uses T-cells from a healthy donor, rather than the patient's own cells, allowing immediate availability. Autologous therapy, however, uses a patient's own cells or tissues, which are collected, processed outside the body, and then reintroduced to the same individual.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRBU">CRBU stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><p>CRBU stock is up 52% this year and approximately 3% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-sales-in-us-rise-1.6-percent-in-october/cL2NX8OR3CR">Ford Sales In US Rise 1.6% In October On Continued Truck Demand</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Rising stock market chart on a trading board background.

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For  Cancer Treatments

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 

Equity

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 


Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates

Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit

CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities...

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU Shareholders of Caribou Biosciences, Inc. Should Contact The Gross...

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.31	--	--	N/A
Q3 '25	-$0.35	-$0.30	15.25%	BEAT
Q2 '25	-$0.40	-$0.35	13.04%	BEAT
Q1 '25	-$0.43	-$0.43	0.92%	BEAT
Q4 '24	-$0.42	-$0.39	6.58%	BEAT

CRBU
Caribou Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest CRBU News

CRBUCaribou Biosciences Inc